Suchen
Regeneron Pharmaceuticals Inc
REGNZur Watchlist hinzufügen
618.030USD
+5.530+0.90%
Handelsschluss 06/23, 16:00（ET）Kurse um 15 Minuten verzögert
64.79BMarktkapitalisierung
14.55KGV TTM
mehr Informationen über Regeneron Pharmaceuticals Inc Unternehmen
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Regeneron Pharmaceuticals Inc Informationen
BörsenkürzelREGN
Name des UnternehmensRegeneron Pharmaceuticals Inc
IPO-datumApr 02, 1991
CEOSchleifer (Leonard S)
Anzahl der mitarbeiter15106
WertpapierartOrdinary Share
GeschäftsjahresendeApr 02
Addresse777 Old Saw Mill River Road
StadtTARRYTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10591
Telefon17813705000
Websitehttps://www.regeneron.com/
BörsenkürzelREGN
IPO-datumApr 02, 1991
CEOSchleifer (Leonard S)
Führungskräfte von Regeneron Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.80K
+0.07%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.42K
-0.57%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.49K
+0.82%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.78K
+0.04%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+0.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.09K
+0.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.21K
+0.06%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
42.31K
-5.98%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.18K
+0.02%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.07K
+0.02%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Regeneron Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Regeneron Pharmaceuticals Inc sind: Dr. George D. Yancopoulos, M.D., Ph.D
Wie viele Institutionen halten Anteile an Regeneron Pharmaceuticals Inc (REGN)?
Mit Stand vom 2026Q1 halten 2806 Institutionen Anteile an Regeneron Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 94.67M, was 91.89% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1673066.00 gestiegen.
Was ist die größte Einnahmequelle von Regeneron Pharmaceuticals Inc?
Am 2026Q1 erzielte das Geschäft mit Sanofi für Regeneron Pharmaceuticals Inc den höchsten Umsatz in Höhe von 5.88B, was 41.02% des Gesamtumsatzes entspricht.
